CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

Poor penetrability and nonselective distribution of chemotherapeutic drugs are the main obstacles for chemotherapy for triple-negative breast cancer (TNBC). In our work, we developed a DNA-based drug ...

to breast epithelial cancer, in the former using tissue culture and in the latter laser microdissection of stromal tissue both adjacent and distal to breast invasive ductal cancer (IDC). From ...

The incidence was similar between the left and right breasts, with most patients diagnosed with grade 2 invasive ductal carcinoma, no vascular emboli, a human epidermal growth factor receptor 2 score ...

A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP). This is an ASCO ...

In this phase II prospective study that included 101 evaluable patients, 36 of whom had residual disease at surgery, the negative predictive value ... Eligible patients included those with operable ...